Medicenna Therapeutics Corp saw a notable increase in its stock price, closing up 2.86% in the latest trading session.
On the TSX, Medicenna Therapeutics Corp (MDNA.TO) experienced a positive trading day, with shares rising to CA$0.36. This uptick is significant for the company, especially considering its recent financial moves and ongoing developments in its therapeutic programs.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeAdvertisement
Market cap
$37.38M
52W high
$1.97
52W low
$0.34
1W change
+6.58%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 690.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+690.1% Upside
Current Price
C$0.41
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
40.5%
Annualized
90-Day Vol
68.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.44 |
| 60 trading days | C$0.36 | C$0.30 – C$0.44 |
| 90 trading days | C$0.34 | C$0.27 – C$0.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Medicenna's strategic decisions, particularly as it navigates public offerings and potential advancements in its drug development pipeline.
Medicenna's Stock Climbs 2.86% in One Day
With a market cap of CA$32.3 million, Medicenna's stock performance is closely linked to its developmental milestones and how the market perceives it.
Bull case
The recent rise in stock price shows that investors are optimistic about Medicenna's public offerings and the potential for growth as the company advances its clinical programs.
Bear case
Despite the positive movement, Medicenna's lack of profitability and the challenges in biotech development could pose risks for investors seeking stability.
Advertisement
Recent Performance Highlights
Medicenna's stock closed at CA$0.36, marking a 2.86% increase in the last trading session. This rise is particularly noteworthy given the company's recent completion of a public offering, which raised approximately $4.44 million. Investors are likely reacting positively to the potential funding for ongoing clinical trials and research.
Market Sentiment and Future Outlook
The biotech sector can be volatile, but the recent movement in Medicenna's stock suggests growing confidence among investors. As the company continues to advance its clinical programs, including MDNA11 and MDNA113, the market will be watching closely for updates that could further influence stock performance. For more insights on Medicenna's developments, check out our detailed analysis on MDNA.TO.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
